Consumables was Zomedica’s largest product and service line in fiscal 2025, bringing in $20.68M of $32.03M (65%).
| Product and Service | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Consumables | $11.46M | $16.31M | $17.66M | $20.68M | |
| Capital | $7.34M | $8.79M | $9.49M | $9.25M | |
| Trodes | — | — | — | — | |
| Engineering | — | — | — | $1.98M | |
| Instruments | — | — | — | — | |
| Other | $136.00K | $85.00K | $131.00K | $123.00K | |
| Other Revenue | — | — | — | — | |
| Total | $18.93M | $25.19M | $27.29M | $32.03M |
Zomedica brought in $32.03M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. Zomedica regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $27.29M. Consumables was the largest at $20.68M (64.6%), ahead of Capital at $9.25M (28.9%) and Engineering at $1.98M (6.2%). The remaining line, Other, brought in $123.00K.
Compared with fiscal 2024, Consumables grew 17.1% to $20.68M, while Capital fell 2.5% to $9.25M.
Zomedica began breaking out Engineering in fiscal 2025, when it brought in $1.98M.
Therapeutic Devices was Zomedica’s largest segment in fiscal 2025, bringing in $26.20M of $32.03M (82%).
| Segment | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Therapeutic Devices | $18.54M | $23.81M | $24.85M | $26.20M | |
| Therapeutics | — | — | — | — | |
| Development Services | — | — | — | $3.03M | |
| Diagnostics | $391.00K | $1.38M | $2.43M | $2.80M | |
| Total | $18.93M | $25.19M | $27.29M | $32.03M |
Zomedica brought in $32.03M from its three segments in fiscal 2025, the year ended December 31, 2025. Zomedica regrouped these segments after fiscal 2024, so the total does not compare directly with that year's $27.29M. Therapeutic Devices was the largest at $26.20M (81.8%), ahead of Development Services at $3.03M (9.5%) and Diagnostics at $2.80M (8.7%).
Compared with fiscal 2024, Diagnostics grew 15.1% to $2.80M and Therapeutic Devices grew 5.4% to $26.20M.
Zomedica began breaking out Development Services in fiscal 2025, when it brought in $3.03M.
Us was Zomedica’s largest region in fiscal 2025, bringing in $26.46M of $32.03M (83%).
| Geography | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Us | $20.68M | $22.56M | $26.46M |
| Foreign Countries | $4.50M | $4.73M | $5.57M |
| Total | $25.19M | $27.29M | $32.03M |
Zomedica brought in $32.03M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 17.4% from $27.29M in fiscal 2024. Us was the largest at $26.46M (82.6%), ahead of Foreign Countries at $5.57M (17.4%).
Compared with fiscal 2024, Foreign Countries grew 17.8% to $5.57M and Us grew 17.3% to $26.46M. From fiscal 2023 to 2025, combined revenue from these regions grew from $25.19M to $32.03M, a compound annual growth rate of 12.8%. Us' share held steady at about 82.6%.
Zomedica (ZOMDF) reports its revenue by product and service, by segment and by geography. In fiscal 2025, Consumables was its largest product and service line, bringing in $20.68M (64.6% of the total), followed by Capital at $9.25M (28.9%).
Consumables was Zomedica's largest product and service line in fiscal 2025, bringing in $20.68M, or 64.6% of the $32.03M total across its four product and service lines.
Therapeutic Devices was Zomedica's largest segment in fiscal 2025, bringing in $26.20M, or 81.8% of the $32.03M total across its three segments.
Us was Zomedica's largest region in fiscal 2025, bringing in $26.46M, or 82.6% of the $32.03M total across its two regions.
Foreign Countries grew faster than Us in fiscal 2025, up 17.8% from $4.73M to $5.57M. Us grew 17.3% to $26.46M.
Every figure comes from Zomedica's annual financial filings, as reported. Each line keeps the name Zomedica gives it, and years follow its fiscal calendar.
Zomedica's revenue by product and service goes back to fiscal 2021, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.